A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro
Open Access
- 3 September 2014
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 1-4
Abstract
Elevated glucose concentrations lead to increased insulin secretion and suppression of glucagon secretion. In fact, insulin is a physiological inhibitor of glucagon secretion. Type 2 diabetes mellitus (T2DM) patients have defects in insulin secretion. In addition to this, lack of suppression of glucagon secretion under elevated glucose concentrations is also observed in T2DM patients. We have earlier shown that GPR40 activation by CNX-011-67 stimulates glucose stimulated insulin secretion (GSIS). Here we extended our studies to examine the impact of GPR40 activation by CNX-011-67 on glucagon secretion from intact islets under both normal and glucolipotoxic conditions. Glucagon secretion from intact rat islets was suppressed under elevated glucose concentration. Activation of GPR40 by CNX-011-67 further suppressed glucagon secretion. Culturing islets under chronic glucolipotoxic (GL) conditions, we have observed increased high glucose mediated glucagon secretion and content which were reduced with GPR40 activation by CNX-011-67. Interestingly, expression of pre-proglucagon gene (GCG) remained unchanged under glucolipotoxicity in the presence or absence of GPR40 activation. Activation of GPR40 by CNX-011-67 can reduce glucagon secretion from pancreatic islets.Keywords
This publication has 12 references indexed in Scilit:
- CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patientsBMC Pharmacology and Toxicology, 2014
- Chronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activityBMC Cell Biology, 2013
- Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF ratsBMC Pharmacology and Toxicology, 2013
- The Effects of TAK-875, a Selective G Protein-Coupled Receptor 40/Free Fatty Acid 1 Agonist, on Insulin and Glucagon Secretion in Isolated Rat and Human IsletsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet α-cellsJournal of Endocrinology, 2011
- GLP-1 Inhibits and Adrenaline Stimulates Glucagon Release by Differential Modulation of N- and L-Type Ca2+ Channel-Dependent ExocytosisCell Metabolism, 2010
- Inhibition of Ca2+signaling and glucagon secretion in mouse pancreatic α-cells by extracellular ATP and purinergic receptorsAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40Nature, 2003
- Impact of lack of suppression of glucagon on glucose tolerance in humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1999
- Insulin within islets is a physiologic glucagon release inhibitor.Journal of Clinical Investigation, 1984